Login
Companies $TPST
$0.36 +$0.02 (5.32%) After hours
Tempest Therapeutics, Inc. logo

Tempest Therapeutics, Inc.

tempesttx.com

What Do They Do?

Develops cell therapies and small-molecule drug candidates for patients with cancer and certain immune conditions.

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Net income
▼ −3% (Loss)
vs −$3.5M in Q3 FY2025
  • Nov 11, 2026 Tempest exercised its option for Senlang’s in vivo CAR-T platform The license covers development and commercialization rights worldwide, excluding China.
  • Nov 4, 2026 Nasdaq notified Tempest of a minimum-bid-price deficiency Tempest has until May 3, 2027, to regain compliance; otherwise, its shares may be subject to delisting.
  • Oct 26, 2026 The CFO resigned and a new CFO was appointed

Cell therapy added The older report centered on orally available small-molecule oncology therapies and preclinical drug programs. The latest report also includes autologous, allogeneic and in vivo CAR-T candidates for blood cancers, solid tumors and immunology indications.

Who Do They Compete With?

Competes with Ono, Adlai Nortye, Merck, Roche, Exelixis, AstraZeneca, Johnson & Johnson, Bristol Meyers Squibb, Gilead Sciences, Arcellx, Legend Biotech, Allogene, and Cellectis

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support